Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Ferran

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Dermatologic Therapy|September 29, 2022
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis GroupVicenç Rocamora, Laura Crespi, Marta Ferran, et al.
International Journal of Molecular Sciences|February 6, 2021
Interplay between Humoral and CLA<sup>+</sup> T Cell Response against <i>Candida albicans</i> in PsoriasisCarmen de Jesús-Gil, Lídia Sans-de San Nicolàs, Ester Ruiz-Romeu, et al.
Allergy|June 30, 2022
SEB-induced IL-13 production in CLA<sup>+</sup> memory T cells defines Th2 high and Th2 low responders in atopic dermatitisLídia Sans-De San Nicolàs, Ignasi Figueras-Nart, Montserrat Bonfill-Ortí, et al.
International Journal of Dermatology|May 13, 2024
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis GroupAntonio Sahuquillo-Torralba, Miguel Mansilla-Polo, Conrad Pujol-Marco, et al.
Pharmacy (Basel, Switzerland)|May 27, 2026
Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)Mar Llamas-Velasco, Mercedes Hospital, Anna López-Ferrer, et al.
The Journal of Dermatological Treatment|April 29, 2021
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registryMónica Munera-Campos, Jaime Vilar-Alejo, Raquel Rivera, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2023
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis GroupSonsoles Berenguer-Ruiz, Mario Aparicio-Domínguez, Pedro Herranz-Pinto, et al.
JAMA Dermatology|March 30, 2022
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With PsoriasisAstrid M van Huizen, Stef P Menting, Rolland Gyulai, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Dermatologic Therapy|September 29, 2022
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis GroupVicenç Rocamora, Laura Crespi, Marta Ferran, et al.
International Journal of Molecular Sciences|February 6, 2021
Interplay between Humoral and CLA<sup>+</sup> T Cell Response against <i>Candida albicans</i> in PsoriasisCarmen de Jesús-Gil, Lídia Sans-de San Nicolàs, Ester Ruiz-Romeu, et al.
Allergy|June 30, 2022
SEB-induced IL-13 production in CLA<sup>+</sup> memory T cells defines Th2 high and Th2 low responders in atopic dermatitisLídia Sans-De San Nicolàs, Ignasi Figueras-Nart, Montserrat Bonfill-Ortí, et al.
International Journal of Dermatology|May 13, 2024
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis GroupAntonio Sahuquillo-Torralba, Miguel Mansilla-Polo, Conrad Pujol-Marco, et al.
Pharmacy (Basel, Switzerland)|May 27, 2026
Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)Mar Llamas-Velasco, Mercedes Hospital, Anna López-Ferrer, et al.
The Journal of Dermatological Treatment|April 29, 2021
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registryMónica Munera-Campos, Jaime Vilar-Alejo, Raquel Rivera, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2023
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis GroupSonsoles Berenguer-Ruiz, Mario Aparicio-Domínguez, Pedro Herranz-Pinto, et al.
JAMA Dermatology|March 30, 2022
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With PsoriasisAstrid M van Huizen, Stef P Menting, Rolland Gyulai, et al.
Pageof 5